Paris - Delayed Quote EUR

Inventiva S.A. (IVA.PA)

2.1400

0.0000

(0.00%)

At close: January 10 at 5:35:21 PM GMT+1

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, ha

GlobeNewswire 25 days ago

IVA

IVEVF
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva’s Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of D

GlobeNewswire 26 days ago

IVA

IVEVF
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’

GlobeNewswire 30 days ago

IVA

IVEVF
Inventiva reports 2024 Third Quarter Financial Information¹

Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on

GlobeNewswire last month

IVA

IVEVF
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined Gene

GlobeNewswire last month

IVA

IVEVF
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights,gross (1) Total voting rights,net (2) November 4, 2024 87 077 695 100 059 052 99 938 530 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on

GlobeNewswire last month

IVA

IVEVF
The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

Pharma Voice last month

IVA.PA
0.00%
MDGL
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagl

GlobeNewswire last month

IVA

IVEVF
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively.This fifth DMC review confirms the good safety profile of lanifibranor. Dai

GlobeNewswire 2 months ago

IVA

IVEVF
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination

GlobeNewswire 2 months ago

IVA

IVEVF
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

BioPharma Dive 2 months ago

PFE

AKESF

JAZZ
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24-

GlobeNewswire 2 months ago

IVA

IVEVF
Inventiva secures up to $380m for MASH treatment lanifibranor

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Pharmaceutical Technology 2 months ago

IVA.PA
0.00%
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Inventiva SA (NASDAQ:IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro. The company announced it has secured financing of immediately 94.1 million euros ($99.36 million) and up to 348 million euros ($379.55 million) to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor. The Transaction wa

Benzinga 2 months ago

IVA.PA
0.00%
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period

GlobeNewswire 2 months ago

IVA

IVEVF
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva’s Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomi

GlobeNewswire 2 months ago

IVA

IVEVF
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 3 months ago

IVA.PA
0.00%
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key

GlobeNewswire 3 months ago

IVA

IVEVF
Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the same perio

GlobeNewswire 5 months ago

IVA

IVEVF
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH. Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t

GlobeNewswire 5 months ago

IVA

IVEVF

Performance Overview

Return	IVA.PA	CAC 40
YTD	-2.28%	+1.61%
1-Year	-46.57%	+0.06%
3-Year	-80.76%	+2.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inventiva S.A. (IVA.PA)

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Inventiva reports 2024 Third Quarter Financial Information¹

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

The first MASH drug could open the door for others — including GLP-1s

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Inventiva secures up to $380m for MASH treatment lanifibranor

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Performance Overview